[ Tips ] 一分鐘使用導覽
商品編號： TB0585 出版日期： 2020/01/01 作者姓名： Inkpen, Andrew C. 商品類別： Other 商品規格： 12p 再版日期： 地域： United States 產業： Genetic engineering;Pharmaceuticals 個案年度： -
商品敘述：
In July 2019, Pfizer announced that it would spin off its Upjohn division and merge it with Mylan, a specialty and generic drugs firm. Within Pfizer, the Upjohn business unit was a conduit for Pfizer drugs going off-patent. Divesting the Upjohn business would allow Pfizer to focus on innovative drugs and exit the generics sector. Combining Upjohn with Mylan would create a new company that would compete in branded prescription drugs, generics, biosimilars, and over-the-counter medicines. Cost synergies from the merger of $1 billion were projected. Under the terms of the agreement, each Mylan share would be converted into one share of the new company. Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%.
涵蓋領域：
相關資料：
Case Teaching Note, (TB0586), 4p, by Andrew C. Inkpen
哪些人也有訂購？